New products and changes introduced over the last week include the Goldman Sachs Small/Mid Cap Value Fund; the Perritt Low Priced Stock Fund; an expanded advisory role for the advisor of the Vanguard Windsor II Fund; a new version of LPL Financial’s Portfolio Manager; and an integrated platform for Wells Fargo’s health savings accounts and 401(k) services.
In addition, NASDAQ OMX announced expanded availability of some of its global indexes; AdvisorShares announced the launch for its YieldPro ETF; Envestnet launched liquid endowment portfolios; First Trust launched the Dorsey Wright Focus 5 ETF; and Scivantage launched the next generation of its Scivantage Investor platform.
Here are the latest developments of interest to advisors:
1) Goldman Sachs Asset Management Launches Small/Mid Cap Value Fund
Goldman Sachs Asset Management (GSAM) has announced the launch of the Goldman Sachs Small/Mid Cap Value Fund (GMVAX, A shares; GSMVX, I shares). The fund seeks long-term capital appreciation in a portfolio of small- and mid-cap securities that portfolio management believes are undervalued and have potential attractive risk-reward profiles.
Top 5 Defense Stocks To Watch For 2015: Thor Industries Inc.(THO)
Thor Industries, Inc., together with its subsidiaries, manufactures and sells a range of recreation vehicles and small and mid-size buses, as well as related parts and accessories in the United States and Canada. The company offers a range of travel trailers and motorhomes under the trade name of Airstream, which include Airstream Safari, International, Flying Cloud, and Bambi travel trailers, as well as Interstate Class B motorhomes. It also manufactures and sells conventional travel trailers and fifth wheels under the trade names of Dutchmen, Four Winds, Aero, Grand Junction, Colorado, Cruiser, Seville, Zinger, and Sunset Trail; travel trailers and fifth wheels under trade names of Montana, Springdale, Hornet, Sprinter, Outback, Laredo, Everest, Mountaineer, Challenger, Cougar, Komfort, and Trailblazer; and gasoline and diesel Class C, Class A, and Class B motorhomes under the trade names of Four Winds, Hurricane, Windsport, Mandalay, Dutchmen, Chateau, Serrano, Ventura, and Fun Mover. In addition, it manufactures and sells gasoline and diesel Class A motor homes under the trade names of Daybreak, Challenger, Astoria, Tuscany, Outlaw, and Avanti; travel trailers, fifth wheels, truck campers, and park models under the trade name of General Coach; and park models under the trade names of Tranquility, Westchester, and Breckenridge. Further, the company manufactures small and mid-size transit and commercial buses under the trade names of Aerolite, AeroElite, Aerotech, Escort, MST, Transmark, EZ Rider, Axess, Challenger, Defender, Crusader, American Cruiser, Classic Coach, EZ Trans, GC II, and Pacer. It markets its vehicles through independent dealers to municipalities and private purchasers, such as rental car companies and hotels. The company has a joint venture agreement with Cruise America, Inc. to provide short-term rentals of motorized recreation vehicles to the public. Thor Industries was founded in 1980 and is based in Jackson Center, Oh io.
Advisors' Opinion:- [By Lauren Pollock]
Thor Industries Inc.'s(THO) fiscal first-quarter earnings rose 33% on the strength of higher sales and wider margins. But results came in lower than expected.
- [By Seth Jayson]
Thor Industries (NYSE: THO ) reported earnings on June 6. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended April 30 (Q3), Thor Industries met expectations on revenues and beat expectations on earnings per share.
10 Best Low Price Stocks To Watch For 2014: Iberdrola SA (IBE)
Iberdrola SA is a Spain-based company principally engaged in the energy sector. The Company's business is structured in four segments: Network Business, including all the energy transmission and distribution activities, and any other regulated activity originated in Spain, the United Kingdom, the United States and Brazil; Deregulated Business, including electricity generation and sales businesses as well as gas trading and storage businesses carried on by the Group in Spain, Portugal, the United Kingdom and North America; Renewable: activities relating to renewable energies in Spain, the United Kingdom, the United States and the rest of the world; Other Businesses, comprising the engineering and construction businesses and the non-power businesses; and Corporation which includes the costs of the Group's structure (Single Corporation), of the administration services of the corporate areas that are subsequently invoiced to the other companies through either specific service. Advisors' Opinion:- [By Sarah Jones]
Iberdrola SA (IBE), Spain�� biggest power company, fell 3.4 percent to 3.87 euros. Endesa SA (ELE) slumped 4.6 percent to 16 euros, while Acciona SA (ANA), which owns more than 4 gigawatts of wind farms in the country, tumbled 8.5 percent to 37.95 euros. Red Electrica Corp. slid 7.5 percent to 38.34 euros.
10 Best Low Price Stocks To Watch For 2014: RetailMeNot Inc (SALE)
RetailMeNot Inc., incorporated on September 17, 2007, operates digital coupon marketplace, connecting consumers with retailers and brands. As of December 31, 2012, the Company had contracts with more than 10,000 paid retailers. The Company owns and operates digital coupon Websites in the United States (RetailMeNot.com) and the United Kingdom (VoucherCodes.co.uk). The Company�� Websites, mobile applications, e-mail newsletters and alerts and social media presence enable consumers to search for, discover and redeem digital coupons from retailers and brands. Its marketplace features digital coupons across multiple product categories, including clothing; electronics; health and beauty; home and office; travel, food and entertainment; personal and business services; and shoes. It aggregates digital coupons from retailers, performance marketing networks, its user community, its employees and outsourced providers.
Products and Services for Consumers
The Company�� product development approach is centered on building products that enable consumers to discover quality digital coupons, virtually anytime and anywhere, and redeem them online or in-store. The Company�� products and services for consumers are available through its Websites and mobile applications. The Company offers its consumers digital coupons from retailers and brands across multiple product categories. Consumers visiting its marketplace search for and discover digital coupons based on retailer name, product, category, digital coupon type, popularity, success rate and other characteristics. Once a consumer discovers a relevant digital coupon, the consumer clicks on that digital coupon and is directed to the Website of the respective retailer, where the consumer is able to purchase products and redeem the digital coupon.
The Company�� mobile applications allow consumers to shop when they want, where they want. Consumers use its mobile applications to discover, store for use later and access the digit! al coupons they want and to redeem them both online and in-store. They can browse top digital coupons, stores and product category listings. Its mobile applications allow users to share digital coupons with others through e-mail, text message or through social media channels. In addition, utilizing location-based technology, the RetailMeNot iPhone application notifies consumers of savings opportunities when they are shopping near one of 575 geo-fenced shopping malls by sending consumers alerts for digital coupons that can be used in these malls. Consumers can redeem these digital coupons by scanning the barcode at the retailer�� register or by having the sales associate enter the promotional code shown on the consumer�� mobile screen into their point-of-sale system.
Using the Company�� geo-location technology, users that opt in receive an alert when they are near a shopping mall. The alert lists digital coupons that can be redeemed at certain stores within that mall. The mobile application also allows consumers to discover and redeem digital coupons online and to find nearby stores where the digital coupon can be utilized. Consumers can subscribe to receive its periodic e-mail newsletter and alerts. Its e-mail newsletter allows consumers to stay informed about featured digital coupons, while its alerts notify consumers when digital coupons from their preferred retailers become available. As of March 31, 2013, it had over nine million subscribers to its free e-mail newsletters and alerts.
Consumers can engage with the Company on social media channels, such as Facebook, Google+, Pinterest and Twitter, to receive promotional messages from retailers and brands. In addition, it engages consumers through social and gamification features in the Community section of RetailMeNot.com, including the ability to earn points, track dollars users have helped others save, view rankings, earn badges and win prizes.
Products and Services for Retailers
The Company ! provides ! retailers and brands with access to new customers through multiple channels online on its Websites and mobile applications, by e-mail newsletters and alerts and its social media presence, and in-store by displaying a digital coupon on a mobile device or presenting a printed coupon. It allows retailers to provide digital coupons across these multiple channels. It provides its paid retailers with a range of paid placement opportunities. Its placement opportunities include placement within the top coupon carousel of its homepage, the side rail of its category pages, its weekly e-mail newsletter, solo retailer newsletter campaigns and on the landing screen of its mobile applications. It charges a fee for these advertising tools on a campaign basis for a given period of time.
The Company competes with dealspl.us, bradsdeals, dealnews, savings.com, Tech Bargains and Coupon Cabin.
Advisors' Opinion:- [By Rich Bieglmeier]
RetailMeNot Inc (NASDAQ:SALE) will report its first quarter 2014 financial results and business outlook on Monday, May 5, 2014 after market close. Following the release of the Company's financial results, Cotter Cunningham, CEO, and Doug Jeffries, CFO, will host a conference call to discuss the results at 5:00 pm Eastern Time (4:00 pm Central Time).
10 Best Low Price Stocks To Watch For 2014: Star Scientific Inc (STSI)
Star Scientific, Inc. (Star Scientific), incorporated on June 24, 1985, is engaged in the manufacturing and production of dietary supplements. The Company�� operating subsidiaries manufacture, distribute and sell consumer products and dietary supplements. Its segment includes dietary supplements. Through its Rock Creek Pharmaceuticals, Inc. (Rock Creek) subsidiary, the Company is engaged in the manufacture, sale, marketing and development of non-nicotine nutraceutical, dietary supplements: Anatabloc, for anti-inflammatory support; the manufacture, sale and marketing of a cosmetic facial cream, and the development of other nutraceuticals, dietary supplements and pharmaceutical products. On December 14, 2012, the Company voted to discontinue the manufacturing, distribution and sale of its dissolvable smokeless tobacco products, Ariva and Stonewall Hard Snuff, as of December 31, 2012. With this change it will no longer be manufacturing or selling any tobacco products.
Rock Creek Pharmaceuticals has been engaged in the development of other dietary supplements and pharmaceutical products, particularly products that have a botanical- based component and that are designed to provide nutritional support in a range of neurological conditions, including Alzheimer�� disease, Parkinson�� disease, schizophrenia, depression, and Hashimoto�� thyroiditis. Rock Creek Pharmaceuticals also has been involved in the development of a cosmetic line of products that utilizes its anatabine compound to improve the appearance of the skin. On September 10, 2012, the Company introduced Anatabloc Facial Creme into the market. As of November 9, 2012, Anatabloc was being sold through its interactive Website, a customer service center and on a consignment basis through GNC, which is a retailer of dietary supplements. The Company uses its anatabine citrate compound in its dietary supplements Anatabloc and Anatabloc Unflavored and its anatabine-based cosmetic product, Anatabloc Facial Creme.
Advisors' Opinion:- [By Bryan Murphy]
The last time I looked at Star Scientific, Inc. (NASDAQ:STSI) was in mid-August, when I pointed out how the stock looked like it was finally beginning a breakout via a move above that nagging ceiling at $2.11. I didn't revisit it in the meantime because STSI peeled back under that key resistance level, and even back under its short-term moving lines. It wasn't a dramatic or painful pullback, but it was more than enough to put the breakout idea on the shelf until further notice.
10 Best Low Price Stocks To Watch For 2014: Healthcare Realty Trust Inc (HR)
Healthcare Realty Trust Incorporated (Healthcare Realty), incorporated in 1993, is a self-managed and self-administered real estate investment trust (REIT) that owns, acquires, manages, finances and develops income-producing real estate properties associated with the delivery of outpatient healthcare services throughout the United States. During the year ended December 31, 2011, the Company disposed of five real estate properties. In January 2012, the Company purchased a 58,295 square foot medical office building in South Dakota. In February 2012, the Company purchased a 23,312 square foot medical office building in North Carolina. The property is 100% leased by two tenants. In January 2012, the Company disposed of two medical office buildings located in Texas. In January 2012, the Company disposed of a medical office building located in Florida. In January 2012, an inpatient facility under construction in South Dakota that was being funded by the Company through a mortgage note was sold. On March 15, 2011, the Company acquired Lakewood MOB, LLC. On March 31, 2011, it acquired HR Ladco Holdings, LLC. Effective October 22, 2013, Healthcare Realty Trust Inc acquired First Hill Medical Building.
As of December 31, 2011, the Company provided property management services for 150 healthcare-related properties nationwide, totaling approximately 10.3 million square feet. The Company�� portfolio of properties is focused on medical office and outpatient sector of the healthcare industry and is diversified by geographic location, tenant and facility type.
Advisors' Opinion:- [By Dividends4Life]
Memberships and Peers: UHT is, a member of the Broad Dividend Achievers��Index and a Dividend Champion. The company's peer group includes: Hersha Hospitality Trust (HT) with a 4.4% yield, Healthcare Realty Trust Incorporated (HR) with a 5.2% yield and LTC Properties Inc. (LTC) with a 5.4% yield.
10 Best Low Price Stocks To Watch For 2014: Varian Medical Systems Inc.(VAR)
Varian Medical Systems, Inc. designs, manufactures, sells, and services equipment and software products for treating cancer with radiotherapy, stereotactic radiotherapy, stereotactic body radiotherapy, stereotactic radiosurgery, and brachytherapy worldwide. Its Oncology Systems segment offers products, such as linear accelerators, brachytherapy afterloaders, treatment simulation and verification equipment, and accessories; and information management, treatment planning, and image processing software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, doctors? offices, and cancer care clinics. The company?s X-ray Products segment provides x-ray tubes for use in a range of applications, including computed tomography scanning, radiographic or fluoroscopic imaging, mammography, special procedures, and industrial applications; and flat panel digital image detectors for filmless x-ray imaging. It sells t hese products to imaging systems original equipment manufacturers that incorporate them into their medical diagnostic, dental, veterinary, and industrial imaging systems; independent service companies; and directly to end-users. The company also designs, manufactures, sells, and services Linatron x-ray accelerators, imaging processing software, and image detection products for security and inspection purposes, such as cargo screening at ports and borders, and nondestructive examination in various applications. In addition, it develops products and systems for delivering proton therapy; and technologies in the areas of digital X-ray imaging technology, volumetric and functional imaging, improved X-ray sources, and technology for security and cargo screening applications. The company was formerly known as Varian Associates, Inc. and changed its name to Varian Medical Systems, Inc. in April 1999. Varian Medical Systems, Inc. was founded in 1948 and is headquartered in Palo Alto , California.
Advisors' Opinion:- [By Monica Gerson]
Varian Medical Systems (NYSE: VAR) is projected to post its Q4 earnings at $1.12 per share on revenue of $779.02 million.
Thermo Fisher Scientific (NYSE: TMO) is estimated to report its Q3 earnings at $1.28 per share on revenue of $3.18 billion.
- [By Holly LaFon]
Varian Medical Systems (VAR) has been a staple in our portfolio since the fall of 2005. The stock has rebounded smartly, up +31% from its April 2013 lows through the first quarter. Varian continues to be the global market share and technological leader in the radiation oncology business. Unfortunately, the incidence of cancer continues its deadly growth. In the U.S. alone, the American Cancer Society projects that some 1.7 million people will be diagnosed with cancer. Expectations of new cancer cases around the world are approaching 25 million over the next three decades. Of these new cases, approximately two-颅��hirds will be treated with some sort of radiation therapy. Varian has been at the forefront of linear particle accelerator since the late 1940's. Today the Company's installed base numbers over 7,300 LINACS across the globe ��a 60% market share. As impressive as that may sound, the availability of state-颅��f-颅��he-颅��rt radiation therapy (radiosurgery and proton therapy) outside of the U.S. is woefully low. The developed world has access to 35 to 110 LINACS per million people over the age of 65. In the U.S., it's 110 LINACS per million. Western Europe and Japan is 35 to 65 per million. In India, Africa, Eastern Europe and Southeast Asia there are between 1 and 20 machines per million. In China there is less than 10 machines per million. Complementing the Company's long-颅��erm growth opportunity in radiation therapy is the secular trend in the "digitization of radiology," which is a key driver of their lucrative software and flat-颅��anel services business, plus their X-颅��ay tube replacement business that sells into the installed base of competing LINACS. The Company's initiatives to drive greater productivity continue to bear fruit. In 2013 sales per employee increased 14% and operating income per employee increased 20% over 2012 levels. Such productivity has helped the Company offset the continuing losses as they rollout their prot
- [By Ben Levisohn]
Varian Medical Systems (VAR) and Stryker (SYK) are heading in opposite directions after reporting very different earnings after the close today.
Getty ImagesShares of Stryker have gained 0.5% to $79–they were up as much as 3.1% at $81–after reporting a profit of $1.23, beating forecasts for $1.22, while revenue came in at $2.47 billion, ahead of forecasts for $2.43 billion. Stryker also said that its full year earnings would come in between $4.74 and $4.90 using new amortization rules. Because of that change it’s hard to tell how that compares to consensus estimates for $4.57.
Varian, meanwhile, has dropped 0.6% to $82 after it said it earned 91 cents a share, up 6% from a year ago and ahead of analyst forecasts for 90 cents, according to FactSet. Varian also predicted that full-year earnings would come in between $4.22 and $4.32 a share, straddling the consensus estimate of $4.29.
- [By Seth Jayson]
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Varian Medical Systems (NYSE: VAR ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Varian Medical Systems doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue increased 7.2%, and inventory increased 13.0%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue grew 6.7%, and inventory increased 13.0%. Over the sequential quarterly period, the trend looks healthy. Revenue grew 13.3%, and inventory grew 0.6%.
10 Best Low Price Stocks To Watch For 2014: Vical Incorporated(VICL)
Vical Incorporated engages in the research and development of biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its products include Allovectin, a Phase III clinical trial product to treat metastatic melanoma; CyMVectin prophylactic vaccine for cytomegalovirus, which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic and prophylactic vaccines for herpes simplex type 2 virus, which is under preclinical trial to prevent and protect against recurring flare-ups, reduce viral shedding ,and transmission. The company, through corporate collaborations, develops TransVax, which is in Phase III clinical trials to protect against CMV infection after stem cell transplants, as well as in Phase II clinical trial to protect against CMV infection after solid organ transplants; Collategene, an angiogenic therapy enc oding hepatocyte growth factor that is in Phase III clinical trials to induce local growth of blood vessels to restore blood flow to limbs affected by critical limb ischemia; Apex-IHN prophylactic vaccine for infectious hematopoietic necrosis virus for the prevention of infection and disease in farm-raised salmon when exposed to infected wild salmon ; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to increase survival time of dogs with oral melanoma. Vical Incorporated, through government collaboration, develops Prophylactic and/or therapeutic HIV vaccine, a Phase IIb clinical trial product to prevent/treat infection, disease, and/or viral shedding; and Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all 4 dengue serotypes. The company was founded in 1987 and is based in San Diego, California.
Advisors' Opinion:- [By Roberto Pedone]
Vical (VICL) engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. This stock closed up 5.8% to $1.62 in Tuesday's trading session.
Tuesday's Range: $1.53-$1.63
52-Week Range: $1.37-$4.74
Tuesday's Volume: 7.28 million
Three-Month Average Volume: 1.53 millionFrom a technical perspective, VICL bounced higher here right above its recent 52-week low at $1.37 with monster upside volume. This stock recently gapped down big from $3.75 to $1.37 with huge downside volume. That move has now pushed shares of VICL into extremely oversold territory, since its current relative strength index reading is 21.80. Oversold can always get more oversold, but it's also an area where a stock can experience a powerful bounce higher from.
Traders should now look for long-biased trades in VICL as long as it's trending above its 52-week low at $1.37 and then once it sustains a move or close above Tuesday's high of $1.63 with volume that hits near or above 1.53 million shares. If we get that move soon, then VICL will set up to re-fill some of its previous gap down zone that started at $3.75. Some possible upside targets if VICL gets into that gap with volume are $2.25 to $2.50.
- [By Rich Bieglmeier]
[Related -Vical (VICL) Licenses Vaxfectin Adjuvant For Use In Malaria Vaccines To Cyvax]
Vical researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases.
- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Vical (NASDAQ: VICL ) has received a distressing two-star ranking.
- [By Roberto Pedone]
Another stock that's starting to trend within range of triggering a major breakout trade is Vical (VICL), which engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. This stock has been hit hard by the sellers over the last six months, with shares off sharply by 65%.
If you look at the chart for Vical, you'll notice that this stock has been trending sideways and consolidating over the last two months, with shares moving between $1.01 on the downside and $1.35 on the upside. Shares of VICL have started to uptrend over the last few weeks, with shares moving higher from its low of $1.01 to its recent high of $1.35 a share. During that move, shares of VICL have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now taken shares of VICL back above its 50-day moving average of $1.16 share and it's quickly pushing the stock within range of triggering a major breakout trade.
Traders should now look for long-biased trades in VICL if it manages to break out above some near-term overhead resistance at $1.35 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.17 million shares. If that breakout hits soon, then VICL will set up to re-test or possibly take out its next major overhead resistance level at $1.53 a share to its gap-down day high of $1.61 a share. Any high-volume move above those levels will then give VICL a chance to re-fill some of its previous gap-down-day zone from last August that started at $3.70 a share.
Traders can look to buy VICL off any weakness to anticipate that breakout and simply use a stop that sits just below its 50-day moving average at $1.20 a share or near more support at $1.10 a share. One can also buy VICL off strength once it starts to cle
No comments:
Post a Comment